Agile Therapeutics (AGXRW) 10-Q 13 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 13, 2014
Document and Entity Information	'	'
Entity Registrant Name	'AGILE THERAPEUTICS INC	'
Entity Central Index Key	'0001261249	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	18,592,968
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Balance_Sheets

Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$45,679,880	$2,119,646
Prepaid expenses	1,369,494	146,704
Total current assets	47,049,374	2,266,350
Property and equipment, net of accumulated depreciation of $273,092 in 2013 and $280,823 in 2014	11,997,697	11,963,079
Deferred financing costs, net	115,693	157,499
Prepaid expenses, long-term	1,677,434	'
Other assets	18,208	18,208
Total assets	60,858,406	14,405,136
Current liabilities:	'	'
Accounts payable	2,654,871	715,454
Accrued expenses	660,139	379,164
Loan payable, current portion	3,559,743	5,105,407
Warrant liability	365,914	644,478
Total current liabilities	7,240,667	6,844,503
Loan payable, long-term	11,241,442	9,769,528
Commitment and contingencies	'	'
Stockholders' (deficit) equity:	'	'
Preferred stock, $.0001 par value, authorized 10,000,000 shares; issued 0 shares outstanding at December 31, 2013 and September 30, 2014	'	'
Common stock, $.0001 par value, authorized 150,000,000 shares; issued 109,321 and outstanding 103,536 shares at December 31, 2013 and issued 18,598,754 and outstanding 18,592,968 shares at September 30, 2014	1,860	88
Additional paid-in capital	169,921,290	46,872,723
Accumulated deficit	-127,546,853	-118,314,383
Total stockholders' (deficit) equity	42,376,297	-71,441,572
Total liabilities, convertible preferred stock and stockholders' (deficit) equity	60,858,406	14,405,136
Series A-1, 8%, non-cumulative convertible preferred stock	'	'
Current liabilities:	'	'
Convertible preferred stock	'	898,305
Series A-2 convertible preferred stock	'	'
Current liabilities:	'	'
Convertible preferred stock	'	543,623
Series B, 8% non-cumulative, convertible preferred stock	'	'
Current liabilities:	'	'
Convertible preferred stock	'	44,928,382
Series C, 12% non-cumulative, convertible preferred stock	'	'
Current liabilities:	'	'
Convertible preferred stock	'	$22,862,367

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accumulated depreciation	$280,823	$273,092
Preferred stock, par value (in dollars per share)	$0.00	'
Preferred stock, authorized	10,000,000	'
Preferred stock, issued	0	'
Preferred stock, outstanding	0	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized	150,000,000	'
Common stock, issued	18,598,754	109,321
Common stock, outstanding	18,592,968	103,536
Series A-1, 8%, non-cumulative convertible preferred stock	'	'
Convertible preferred stock, par value (in dollars per share)	'	$0.00
Convertible preferred stock, authorized	'	284,743
Convertible preferred stock, issued	'	137,787
Convertible preferred stock, outstanding	'	137,787
Series A-2 convertible preferred stock	'	'
Convertible preferred stock, par value (in dollars per share)	'	$0.00
Convertible preferred stock, authorized	'	99,178
Convertible preferred stock, issued	'	66,116
Convertible preferred stock, outstanding	'	66,116
Series B, 8% non-cumulative, convertible preferred stock	'	'
Convertible preferred stock, par value (in dollars per share)	'	$0.00
Convertible preferred stock, authorized	'	4,510,066
Convertible preferred stock, issued	'	4,510,066
Convertible preferred stock, outstanding	'	4,510,066
Series C, 12% non-cumulative, convertible preferred stock	'	'
Convertible preferred stock, par value (in dollars per share)	'	$0.00
Convertible preferred stock, authorized	'	2,711,734
Convertible preferred stock, issued	'	1,578,400
Convertible preferred stock, outstanding	'	1,578,400

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Operating expenses:	'	'	'	'
Research and development	$4,602,513	$2,397,898	$8,387,693	$7,895,352
General and administrative	1,446,371	923,491	3,603,528	2,903,468
Total operating expenses	6,048,884	3,321,389	11,991,221	10,798,820
Loss from operations	-6,048,884	-3,321,389	-11,991,221	-10,798,820
Other income (expense)	'	'	'	'
Interest expense	-392,009	-378,228	-1,173,723	-1,134,684
Interest income	1,288	152	1,425	1,584
Change in fair value of warrants	86,243	8,510	278,564	24,856
Loss before benefit from income taxes	-6,353,362	-3,690,955	-12,884,955	-11,907,064
Benefit from income taxes	'	'	3,652,485	'
Net loss	($6,353,362)	($3,690,955)	($9,232,470)	($11,907,064)
Net loss per common share:	'	'	'	'
Basic and Diluted (in dollars per share)	($0.34)	($71.67)	($1.03)	($245.88)
Weighted-average shares outstanding:	'	'	'	'
Basic and Diluted (in shares)	18,592,968	51,499	8,967,324	48,427

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities	'	'
Net loss	($9,232,470)	($11,907,064)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	7,730	9,149
Noncash stock bonus	80,000	79,509
Noncash stock based compensation	973,354	1,095,452
Noncash interest	138,723	69,246
Change in fair value of warrants	-278,564	-24,856
Changes in operating assets and liabilities:	'	'
Prepaid expenses	-2,900,224	41,672
Accounts payable and accrued expenses	2,220,392	-540,063
Net cash (used in) operating activities	-8,991,059	-11,176,955
Cash flows from investing activities	'	'
Acquisition of property and equipment	-42,348	-4,892,281
Net cash used in investing activities	-42,348	-4,892,281
Cash flows from financing activities	'	'
Proceeds from convertible bridge notes	3,000,000	'
Cash paid for financing costs	-150,000	'
Proceeds from issuance of common stock in initial public offering, net of offering costs	49,743,641	'
Net cash provided by financing activities	52,593,641	'
Net increase (decrease) in cash and cash equivalents	43,560,234	-16,069,236
Cash and cash equivalents, beginning of period	2,119,646	20,013,754
Cash and cash equivalents, end of period	45,679,880	3,944,518
Supplemental cash flow information	'	'
Interest paid	1,035,000	1,035,000
Supplemental disclosure of noncash financing activities	'	'
Conversion of preferred stock into common stock	69,232,677	'
Conversion of notes payable and interest into common stock	$3,020,667	'

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Organization and Basis of Presentation	'
Organization and Basis of Presentation	'
	1. Organization and Basis of Presentation
	Nature of Operations
	Agile Therapeutics, Inc. (the “Company”) was incorporated in Delaware on December 22, 1997. The Company is engaged in research and development of transdermal patch technology for use in contraception. The Company’s activities since inception have consisted principally of raising capital, and performing research and development. The Company is headquartered in Princeton, New Jersey.
	The Company is devoting substantially all of its efforts toward research and development of its transdermal patch for use in contraception, and raising capital. The Company has not generated product revenue to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, the difficulties inherent in the development of commercially usable products, the potential need to obtain additional capital necessary to fund the development of its products, and competition from larger companies. The Company has incurred losses each year since inception. As of September 30, 2014, the Company had an accumulated deficit of approximately $127.5 million.
	The Company has financed its operations to date primarily through the issuance and sale of its common stock in its initial public offering (see Note 8), private placements of its convertible preferred stock, venture loans, and non-dilutive grant funding. The Company expects to continue to incur net losses into the foreseeable future.
	Basis of Presentation
	The accompanying unaudited interim condensed financial statements have been prepared by the Company, without audit, in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. It is recommended that these interim condensed financial statements be read in conjunction with the financial statements and related notes that appear in the Company’s final prospectus filed with the SEC on May 22, 2014, relating to the Company’s Registration Statements on Form S-1 (File No. 333-194621) for the Company’s initial public offering.
	In the opinion of management, the unaudited interim condensed financial statements reflects all adjustments, which are normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods have been made. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future period.

Summary_of_Significant_Account

Summary of Significant Accounting Polices	9 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Polices	'
Summary of Significant Accounting Polices	'
	2. Summary of Significant Accounting Polices
	The Company’s complete listing of significant accounting policies are described in Note 2 to the Company’s audited financial statements as of December 31, 2013 included in the Prospectus that forms a part of the Company’s Registration Statement on Form S-1 dated May 22, 2014.
	Use of Estimates
	The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances.
	The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for preferred stock warrants, stock-based compensation, income taxes, and accounting for research and development costs. Actual results could differ from those estimates.
	Stock Split
	On May 5, 2014, the Company effected a 1.4-for-1 stock split of the Company’s common stock. All share and per share amounts of common stock contained in the Company’s financial statements have been restated for all periods to give retroactive effect to the stock split. The shares of common stock retained a par value of $0.0001 per share. Accordingly, the stockholders’ deficit reflects the stock split by reclassifying from “Additional paid-in Capital” to “Common Stock” in an amount equal to the par value of the increased shares resulting from the stock split.
	Fair Value of Financial Instruments
	In accordance with ASC 825, Financial Instruments, disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. Cash and cash equivalents are carried at fair value (see Note 3).
	Financial instruments, including accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.
	Warrants
	The Company accounts for its warrants to purchase redeemable convertible stock in accordance with ASC 480, Distinguishing Liabilities from Equity. ASC 480 requires that a financial instrument, other than outstanding share, that, at inception, is indexed to an obligation to repurchase the issuer’s equity shares, regardless of the timing or the probability of the redemption feature, and may require the issuer to settle the obligation by transferring assets be classified as a liability. The Company measures the fair value of its warrant liability using an option pricing model with changes in fair value recognized as increases or reductions to other income (expense) in the statement of operations.
	In connection with the completion of the Company’s initial public offering in May 2014, the warrants to purchase shares of Series A-1 and Series A-2 preferred stock expired unexercised and the warrants to purchase shares of Series C preferred stock automatically converted into warrants to purchase shares of common stock.  Warrants with non-standard anti-dilution provisions (referred to as down round protection) are classified as liabilities and re-measured each reporting period.
	Stock-Based Compensation
	The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation. The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant- date fair value estimated using the weighted-average assumption of the Black- Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital.
	Awards for consultants are accounted for under ASC 505-50, Equity Based Payments to Non-Employees. Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest.
	Net Loss Per Share
	Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of diluted net loss per share calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.
	The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive (in common equivalent shares):
		September 30
		2013		2014
	Convertible preferred stock	8,809,325		—
	Convertible preferred stock warrants	287,028		—
	Common stock warrants	—		62,505
	Common stock options	1,272,090		1,785,452
	Total	10,368,443		1,847,957
	The following tables summarizes the Company’s computation of basic and diluted net loss per share for common stockholders:
		Three Months Ended
		September 30
		2013			2014
	Numerator
	Net loss	$	(3,690,955	)	$	(6,353,362	)
	Denominator
	Denominator for basic and diluted net loss per share	51,499			18,592,968
	Net loss per share, basic and diluted	$	(71.67	)	$	(0.34	)
		Nine Months Ended
		September 30
		2013			2014
	Numerator
	Net loss	$	(11,907,064	)	$	(9,232,470	)
	Denominator
	Denominator for basic and diluted net loss per share	48,427			8,967,324
	Net loss per share, basic and diluted	$	(245.88	)	$	(1.03	)
	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-10, which eliminates the concept of a development stage entity, or DSE, in its entirety from GAAP.  Under current guidance, DSEs are required to report incremental information, including inception-to-date financial information, in their financial statements.  A DSE is an entity devoting substantially all of its efforts to establishing a new business and for which either planned principal operations have not yet commenced or have commenced but there has been no significant revenue generated from that business.  Entities classified as DSEs will no longer be subject to these incremental reporting requirements after adopting ASU No. 2014-10.  ASU No. 2014 is effective for fiscal years beginning after December 15, 2014, with early adoption permitted.  Retrospective application is required for the elimination of incremental DSE disclosures.  Prior to the issuance of ASU No. 2014-10, the Company had met the definition of a DSE since its inception.  The Company elected to adopt this ASU early, and therefore it has eliminated the incremental disclosures previously required of DSEs, beginning with its Quarterly Report on Form 10-Q for the period ended June 30, 2014.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Measurements	'
Fair Value Measurements	'
	3. Fair Value Measurements
	ASC 820, Fair Value Measurements and Disclosures, describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
	·         Level 1 — Quotes prices in active markets for identical assets and liabilities. The Company’s Level 1 assets and liabilities consist of cash and cash equivalents.
	·         Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. The Company has no Level 2 assets or liabilities.
	·         Level 3 — Unobservable inputs that are supported by little or no market data and which require internal development of assumptions about how market participant price the fair value of the assets or liabilities. The Company’s Level 3 liabilities consist of the warrant liability.
	The Company is required to mark the value of its warrant liability to market and recognize the change in valuation in its statements of operations each reporting period.
	The following table sets forth the Company’s financial instruments measured at fair value by level within the fair value hierarchy as of December 31, 2013 and September 30, 2014.
		Level 1			Level 2		Level 3
	December 31, 2013
	Assets:
	Cash and cash equivalents	$	2,066,156		$	—	$	—
	Total assets at fair value	$	2,066,156		$	—	$	—
	Liabilities:
	Series A-1 warrants	$	—		$	—	$	438,978
	Series A-2 warrants	—			—		64,537
	Series C warrants	—			—		140,963
	Total liabilities at fair value	$	—		$	—	$	644,478
	The significant assumptions used in preparing the option pricing model for valuing the Company’s warrants as of December 31, 2013 include (i) volatility (104.8%), (ii) risk free interest rate of 1.94% (estimated using treasury bonds with a 6 year life), (iii) strike price ($10.00) for the Series A-1 and Series A-2 warrants and $15.00 for the Series C warrants, (iv) fair value of Series A-1 preferred stock ($4.17), Series A-2 preferred stock ($2.91) and Series C preferred stock ($7.63) and (v) expected life (six years).
	The following is a rollforward of the fair value of Level 3 warrants:
	Beginning balance at December 31, 2013	$	644,478
	Expiration of Series A-1 and Series A-2 warrants	(493,361		)
	Change in fair value	214,797
	Ending balance at September 30, 2014	$	365,914
		Level 1			Level 2		Level 3
	September 30, 2014
	Assets:
	Cash and cash equivalents	$	45,585,118		$	—	$	—
	Total assets at fair value	$	45,585,118		$	—	$	—
	Liabilities:
	Common stock warrants	—			—		365,914
	Total liabilities at fair value	$	—		$	—	$	365,914
	The significant assumptions used in preparing the option pricing model for valuing the Company’s warrants as of September 30, 2014 include (i) volatility (104.8%), (ii) risk free interest rate of 1.78% (estimated using treasury bonds with a 5.25 year life), (iii) strike price ($6.00) for the common stock warrants, (iv) fair value of common stock ($7.30) and (v) expected life (5.25 years).
	There were no transfers between Level 1, 2 or 3 during 2013 or 2014. If the Company’s estimates regarding the fair value of its warrants are inaccurate, a future adjustment to these estimated fair values may be required. Additionally, these estimated fair values could change significantly.

Prepaid_Expenses

Prepaid Expenses	9 Months Ended
	Sep. 30, 2014
Prepaid Expenses	'
Prepaid Expenses	'
	4. Prepaid Expenses
	Prepaid expenses consist of the following:
		December 31,		September 30,
		2013		2014
	Prepaid clinical trial expense	$	—	$	1,877,434
	Prepaid insurance	48,055		1,102,249
	Other	98,649		67,245
	Total prepaid expenses	$	146,704	$	3,046,928
	Prepaid expenses, short-term	$	146,704	$	1,369,494
	Prepaid expenses, long-term	—		1,677,434
	Total prepaid expenses	$	146,704	$	3,046,928
	Prepaid expenses, long-term represents non-refundable advances to the Company’s clinical research organization which will be applied against final invoices.

Accrued_Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2014
Accrued Liabilities	'
Accrued Liabilities	'
	5. Accrued Liabilities
	Accrued liabilities consist of the following:
		December 31,		September 30,
		2013		2014
	Employee bonuses	$	238,941	$	435,482
	Other	140,223		224,657
	Total accrued liabilities	$	379,164	$	660,139

Convertible_Note_Financing

Convertible Note Financing (Convertible Notes)	9 Months Ended
	Sep. 30, 2014
Convertible Notes	'
Debt	'
Convertible Note Financing	'
	6. Convertible Note Financing
	On April 28, 2014, the Company and certain of the Company’s existing preferred stockholders, all of whom qualify as accredited institutional investors, entered into a Convertible Subordinated Note Purchase Agreement pursuant to which such holders agreed to loan the Company an aggregate of $3.0 million. The Company issued Convertible Promissory Notes (the “Notes”) to evidence its payment obligations with respect to the $3.0 million. The Notes had an interest rate of 8%, accruing daily and compounding annually. The Notes are convertible into unregistered equity securities of the Company upon the occurrence of events stated therein. The Notes and accrued interest automatically converted into 503,450 shares of common stock at $6.00 per share which was equal to the purchase price at which shares were sold to the public in an underwritten public offering (see Note 8). The Notes were subordinate to the Company’s term loan with Oxford Finance LLC.

Term_Loan_Amendment

Term Loan Amendment (Term loan)	9 Months Ended
	Sep. 30, 2014
Term loan	'
Debt	'
Term Loan Amendment	'
	7. Term Loan Amendment
	In January 2014 the Company amended its Loan Agreement with Oxford Finance whereby the interest only period was extended for three months (through April 1, 2014). The interest only period was extended for an additional three months (through July 1, 2014) as a result of the Company’s $3.0 million convertible note financing in which was completed in April 2014 (see Note 6).
	The interest only period was further extended for an additional six months (through January 1, 2015) and the maturity date of the loan was extended to July 1, 2017 as a result of the completion of the Company’s initial public offering (see Note 8). In connection with the amendment to the Loan Agreement the Company has paid Oxford Finance a total of $150,000.  The $150,000 has been offset against the amount of the loan and is being amortized to interest expense.
	At September 30, 2014, the Company believes it is in compliance with the Loan Agreement.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity	'
Stockholders' Equity	'
	8. Stockholders’ Equity
	Initial Public Offering and Related Transactions
	On May 29, 2014, the Company completed its initial public offering selling 9,166,667 shares of common stock at $6.00 per share.  Proceeds from the Company’s initial public offering, net of underwriting discounts and commissions and other offering costs were $49.7 million.
	In addition, each of the following occurred in connection with the completion of the Company’s IPO on May 29, 2014:
	·         the conversion of all outstanding shares of convertible preferred stock into 8,809,325 shares of the Company’s common stock
	·         the conversion of the aggregate principal amount of $3.0 million and accrued interest under the Company’s outstanding convertible subordinated promissory notes into 503,450 shares of the Company’s common stock.
	On May 7, 2014, the Company filed an amendment to its amended and restated certificate of incorporation which, among other things, revised the automatic conversion provision relating to the Series C Preferred Stock, Series B Preferred Stock, Series A-1 Preferred Stock and Series A-2 Preferred Stock. Following such amendment, the Series C, the Series B, the Series A-1 and A-2 Preferred Stock automatically converted into shares of common stock at the then effective conversion price upon:
	(i) the closing of an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, covering the offer and sale of common stock from which the Company receives gross proceeds of at least $45,000,000 or (ii) the affirmative vote of the holders of at least a majority of the voting power the Series C Preferred Stock, the Series B Preferred Stock and the Series A-1 Preferred Stock, respectively, after first giving effect, if in conjunction with a public offering which does not meet the standards set forth in clause (i) above, to any adjustment of the conversion price for each series of preferred stock to which it would otherwise be entitled by virtue of such public offering.
	On May 29, 2014, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of shares of its common stock. The Company’s board of directors (the “Board”) and stockholders previously approved the Restated Certificate effective as of and contingent upon the closing of the Company’s initial public offering.
	The Restated Certificate amends and restates in its entirety the Company’s second amended and restated certificate of incorporation, as amended. The Restated Certificate, among other things: (i) authorizes 150,000,000 shares of common stock; (ii) eliminates all references to the previously existing series of preferred stock; (iii) authorizes 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; (iv) provides that the Board be divided into three classes with staggered three-year terms, with one class of directors to be elected at each annual meeting of the Company’s stockholders; (v) provides that directors may only be removed with cause and only upon the affirmative vote of holders of at least 75% of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors; (vi) provides that only the Board, the chairman of the Board, if one is appointed, or the chief executive officer may call a special meeting of stockholders; and (vii) requires that any action instituted against the Company’s officers or directors in connection with their service to the Company be brought in the State of Delaware.
	Convertible Preferred Stock
	Prior to its conversion in the IPO, the Company’s convertible preferred stock was classified as temporary equity on its balance sheets instead of stockholders’ (deficit) in accordance with authoritative guidance for the classification and measurement or redeemable securities.  Upon certain change in control events that were outside of the Company’s control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock could cause its redemption.
	Stock-Based Compensation Expense
	Stock-based compensation expense related to stock options was allocated as follows:
		Three Months Ended
		September 30
		2013		2014
	Research and development	$	144,267	$	148,244
	General and administrative	115,027		232,765
	Total stock-based compensation expense	$	259,294	$	381,009
		Nine Months Ended
		September 30
		2013		2014
	Research and development	$	728,999	$	483,677
	General and administrative	366,453		489,677
	Total stock-based compensation expense	$	1,095,452	$	973,354

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Taxes	'
Income Taxes	'
	9. Income Taxes
	Sale of New Jersey Net Operating Losses
	The Company received approval to sell a portion of the Company’s New Jersey net operating losses (NOLs) as part of the Technology Business Tax Certificate Program sponsored by The New Jersey Economic Development Authority. Under the program, emerging biotechnology companies with unused NOLs and unused research and development credits are allowed to sell these benefits to other companies. On February 27, 2014, the Company completed the sale of NOLs totaling approximately $39.1 million for net proceeds of approximately $3.6 million. Such proceeds are reflected as a tax benefit for nine months ended September 30, 2014.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions	'
Related Party Transactions	'
	10. Related Party Transactions
	Effective March 17, 2014, one of the Managing Partners of SmartPharma LLC or SmartPharma, an entity which provides commercial and business development consulting services to the Company was appointed Chief Commercial Officer. In connection with the appointment of this individual as Chief Commercial Officer, the Company amended its consulting agreement with SmartPharma to remove this individual from the list of persons providing service under the consulting agreement. SmartPharma invoiced the Company $26,100 and $100,400 of fees for the three and nine months ended September 30, 2014.

Summary_of_Significant_Account1

Summary of Significant Accounting Polices (Polices)	9 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Polices	'
Use of Estimates	'
	Use of Estimates
	The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances.
	The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for preferred stock warrants, stock-based compensation, income taxes, and accounting for research and development costs. Actual results could differ from those estimates.
Stock Split	'
	Stock Split
	On May 5, 2014, the Company effected a 1.4-for-1 stock split of the Company’s common stock. All share and per share amounts of common stock contained in the Company’s financial statements have been restated for all periods to give retroactive effect to the stock split. The shares of common stock retained a par value of $0.0001 per share. Accordingly, the stockholders’ deficit reflects the stock split by reclassifying from “Additional paid-in Capital” to “Common Stock” in an amount equal to the par value of the increased shares resulting from the stock split.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	In accordance with ASC 825, Financial Instruments, disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. Cash and cash equivalents are carried at fair value (see Note 3).
	Financial instruments, including accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.
Warrants	'
	Warrants
	The Company accounts for its warrants to purchase redeemable convertible stock in accordance with ASC 480, Distinguishing Liabilities from Equity. ASC 480 requires that a financial instrument, other than outstanding share, that, at inception, is indexed to an obligation to repurchase the issuer’s equity shares, regardless of the timing or the probability of the redemption feature, and may require the issuer to settle the obligation by transferring assets be classified as a liability. The Company measures the fair value of its warrant liability using an option pricing model with changes in fair value recognized as increases or reductions to other income (expense) in the statement of operations.
	In connection with the completion of the Company’s initial public offering in May 2014, the warrants to purchase shares of Series A-1 and Series A-2 preferred stock expired unexercised and the warrants to purchase shares of Series C preferred stock automatically converted into warrants to purchase shares of common stock.  Warrants with non-standard anti-dilution provisions (referred to as down round protection) are classified as liabilities and re-measured each reporting period.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation. The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant- date fair value estimated using the weighted-average assumption of the Black- Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital.
	Awards for consultants are accounted for under ASC 505-50, Equity Based Payments to Non-Employees. Any compensation expense related to consultants is marked-to-market over the applicable vesting period as they vest.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of diluted net loss per share calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.
	The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive (in common equivalent shares):
		September 30
		2013		2014
	Convertible preferred stock	8,809,325		—
	Convertible preferred stock warrants	287,028		—
	Common stock warrants	—		62,505
	Common stock options	1,272,090		1,785,452
	Total	10,368,443		1,847,957
	The following tables summarizes the Company’s computation of basic and diluted net loss per share for common stockholders:
		Three Months Ended
		September 30
		2013			2014
	Numerator
	Net loss	$	(3,690,955	)	$	(6,353,362	)
	Denominator
	Denominator for basic and diluted net loss per share	51,499			18,592,968
	Net loss per share, basic and diluted	$	(71.67	)	$	(0.34	)
		Nine Months Ended
		September 30
		2013			2014
	Numerator
	Net loss	$	(11,907,064	)	$	(9,232,470	)
	Denominator
	Denominator for basic and diluted net loss per share	48,427			8,967,324
	Net loss per share, basic and diluted	$	(245.88	)	$	(1.03	)
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-10, which eliminates the concept of a development stage entity, or DSE, in its entirety from GAAP.  Under current guidance, DSEs are required to report incremental information, including inception-to-date financial information, in their financial statements.  A DSE is an entity devoting substantially all of its efforts to establishing a new business and for which either planned principal operations have not yet commenced or have commenced but there has been no significant revenue generated from that business.  Entities classified as DSEs will no longer be subject to these incremental reporting requirements after adopting ASU No. 2014-10.  ASU No. 2014 is effective for fiscal years beginning after December 15, 2014, with early adoption permitted.  Retrospective application is required for the elimination of incremental DSE disclosures.  Prior to the issuance of ASU No. 2014-10, the Company had met the definition of a DSE since its inception.  The Company elected to adopt this ASU early, and therefore it has eliminated the incremental disclosures previously required of DSEs, beginning with its Quarterly Report on Form 10-Q for the period ended June 30, 2014.

Summary_of_Significant_Account2

Summary of Significant Accounting Polices (Tables)	9 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Polices	'
Schedule of outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive	'
	The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive (in common equivalent shares):
		September 30
		2013		2014
	Convertible preferred stock	8,809,325		—
	Convertible preferred stock warrants	287,028		—
	Common stock warrants	—		62,505
	Common stock options	1,272,090		1,785,452
	Total	10,368,443		1,847,957
Summary of computation of basic and diluted net loss per share for common stockholders	'
		Three Months Ended
		September 30
		2013			2014
	Numerator
	Net loss	$	(3,690,955	)	$	(6,353,362	)
	Denominator
	Denominator for basic and diluted net loss per share	51,499			18,592,968
	Net loss per share, basic and diluted	$	(71.67	)	$	(0.34	)
		Nine Months Ended
		September 30
		2013			2014
	Numerator
	Net loss	$	(11,907,064	)	$	(9,232,470	)
	Denominator
	Denominator for basic and diluted net loss per share	48,427			8,967,324
	Net loss per share, basic and diluted	$	(245.88	)	$	(1.03	)

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Measurements	'
Schedule of the Company's financial instruments measured at fair value by level within the fair value hierarchy	'
		Level 1			Level 2		Level 3
	December 31, 2013
	Assets:
	Cash and cash equivalents	$	2,066,156		$	—	$	—
	Total assets at fair value	$	2,066,156		$	—	$	—
	Liabilities:
	Series A-1 warrants	$	—		$	—	$	438,978
	Series A-2 warrants	—			—		64,537
	Series C warrants	—			—		140,963
	Total liabilities at fair value	$	—		$	—	$	644,478
		Level 1			Level 2		Level 3
	September 30, 2014
	Assets:
	Cash and cash equivalents	$	45,585,118		$	—	$	—
	Total assets at fair value	$	45,585,118		$	—	$	—
	Liabilities:
	Common stock warrants	—			—		365,914
	Total liabilities at fair value	$	—		$	—	$	365,914
Schedule of rollforward of the fair value of Level 3 warrants	'
	Beginning balance at December 31, 2013	$	644,478
	Expiration of Series A-1 and Series A-2 warrants	(493,361		)
	Change in fair value	214,797
	Ending balance at September 30, 2014	$	365,914

Prepaid_Expenses_Tables

Prepaid Expenses (Tables)	9 Months Ended
	Sep. 30, 2014
Prepaid Expenses	'
Schedule of prepaid expenses	'
		December 31,		September 30,
		2013		2014
	Prepaid clinical trial expense	$	—	$	1,877,434
	Prepaid insurance	48,055		1,102,249
	Other	98,649		67,245
	Total prepaid expenses	$	146,704	$	3,046,928
	Prepaid expenses, short-term	$	146,704	$	1,369,494
	Prepaid expenses, long-term	—		1,677,434
	Total prepaid expenses	$	146,704	$	3,046,928

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Accrued Liabilities	'
Schedule of accrued liabilities	'
		December 31,		September 30,
		2013		2014
	Employee bonuses	$	238,941	$	435,482
	Other	140,223		224,657
	Total accrued liabilities	$	379,164	$	660,139

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity	'
Schedule of stock-based compensation expense related to stock options	'
		Three Months Ended
		September 30
		2013		2014
	Research and development	$	144,267	$	148,244
	General and administrative	115,027		232,765
	Total stock-based compensation expense	$	259,294	$	381,009
		Nine Months Ended
		September 30
		2013		2014
	Research and development	$	728,999	$	483,677
	General and administrative	366,453		489,677
	Total stock-based compensation expense	$	1,095,452	$	973,354

Organization_and_Basis_of_Pres1

Organization and Basis of Presentation (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Organization and Basis of Presentation	'	'
Accumulated deficit	$127,546,853	$118,314,383

Summary_of_Significant_Account3

Summary of Significant Accounting Polices (Details) (USD $)	0 Months Ended
	5-May-14	Sep. 30, 2014	Dec. 31, 2013
Common stock	'	'	'
Stock split conversion ratio	1.4	'	'
Par value of common stock (in dollars per share)	$0.00	$0.00	$0.00

Summary_of_Significant_Account4

Summary of Significant Accounting Polices (Details 2)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Net loss per share	'	'
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	1,847,957	10,368,443
Convertible preferred stock	'	'
Net loss per share	'	'
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	'	8,809,325
Common stock options	'	'
Net loss per share	'	'
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	1,785,452	1,272,090
Common stock | Warrants	'	'
Net loss per share	'	'
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	62,505	'
Convertible preferred stock | Warrants	'	'
Net loss per share	'	'
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	'	287,028

Summary_of_Significant_Account5

Summary of Significant Accounting Polices (Details 3) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator	'	'	'	'
Net loss	($6,353,362)	($3,690,955)	($9,232,470)	($11,907,064)
Denominator	'	'	'	'
Denominator for basic and diluted net loss per share	18,592,968	51,499	8,967,324	48,427
Net loss per share, basic and diluted (in dollars per share)	($0.34)	($71.67)	($1.03)	($245.88)

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Liabilities:	'	'
Liability	365,914	644,478
Level 3 | Warrants	'	'
Significant assumptions used in preparing the option pricing model for valuing the Company's warrants	'	'
Volatility (as a percent)	104.80%	104.80%
Risk free interest rate (as a percent)	1.78%	1.94%
Life of treasury bonds	'5 years 3 months	'6 years
Expected life	'5 years 3 months	'6 years
Level 3 | Warrants | Common stock	'	'
Significant assumptions used in preparing the option pricing model for valuing the Company's warrants	'	'
Strike price (in dollars per share)	6	'
Stock fair value (in dollars per share)	7.3	'
Level 3 | Warrants | Series A-1 warrants	'	'
Significant assumptions used in preparing the option pricing model for valuing the Company's warrants	'	'
Strike price (in dollars per share)	'	10
Level 3 | Warrants | Series A-1 warrants | Series A-1 Preferred Stock	'	'
Significant assumptions used in preparing the option pricing model for valuing the Company's warrants	'	'
Stock fair value (in dollars per share)	'	4.17
Level 3 | Warrants | Series A-2 warrants	'	'
Significant assumptions used in preparing the option pricing model for valuing the Company's warrants	'	'
Strike price (in dollars per share)	'	10
Level 3 | Warrants | Series A-2 warrants | Series A-2 Preferred Stock	'	'
Significant assumptions used in preparing the option pricing model for valuing the Company's warrants	'	'
Stock fair value (in dollars per share)	'	2.91
Level 3 | Warrants | Series C warrants	'	'
Significant assumptions used in preparing the option pricing model for valuing the Company's warrants	'	'
Strike price (in dollars per share)	'	15
Level 3 | Warrants | Series C warrants | Series C Preferred Stock	'	'
Significant assumptions used in preparing the option pricing model for valuing the Company's warrants	'	'
Stock fair value (in dollars per share)	'	7.63
Recurring | Measured at fair value | Level 1	'	'
Assets:	'	'
Cash and cash equivalents	45,585,118	2,066,156
Total assets at fair value	45,585,118	2,066,156
Recurring | Measured at fair value | Level 3	'	'
Liabilities:	'	'
Total liabilities at fair value	365,914	644,478
Recurring | Measured at fair value | Level 3 | Warrants | Common stock	'	'
Liabilities:	'	'
Liability	365,914	'
Recurring | Measured at fair value | Level 3 | Warrants | Series A-1 warrants	'	'
Liabilities:	'	'
Liability	'	438,978
Recurring | Measured at fair value | Level 3 | Warrants | Series A-2 warrants	'	'
Liabilities:	'	'
Liability	'	64,537
Recurring | Measured at fair value | Level 3 | Warrants | Series C warrants	'	'
Liabilities:	'	'
Liability	'	140,963

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Fair value measurements	'	'
Asset transfers out of Level 1 into Level 2	$0	$0
Asset transfers out of Level 2 into Level 1	0	0
Asset transfers into (out of) Level 3	0	0
Liability transfers out of Level 1 into Level 2	0	0
Liability transfers out of Level 2 into Level 1	0	0
Liability transfers into (out of) Level 3	0	0
Liabilities | Warrants	'	'
Rollforward of the fair value of Level 3 warrants	'	'
Balance at the beginning of the period	644,478	'
Expiration of Series A-1 and Series A-2 warrants	-493,361	'
Change in fair value	214,797	'
Balance at the end of the period	$365,914	'

Prepaid_Expenses_Details

Prepaid Expenses (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Prepaid Expenses	'	'
Prepaid clinical trial expense	$1,877,434	'
Prepaid insurance	1,102,249	48,055
Other	67,245	98,649
Total prepaid expenses	3,046,928	146,704
Prepaid expenses, short-term and long-term	'	'
Prepaid expenses, short-term	1,369,494	146,704
Prepaid expenses, long-term	1,677,434	'
Total prepaid expenses	$3,046,928	$146,704

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accrued Liabilities	'	'
Employee bonuses	$435,482	$238,941
Other	224,657	140,223
Total accrued liabilities	$660,139	$379,164

Convertible_Note_Financing_Det

Convertible Note Financing (Details) (USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	29-May-14	Apr. 28, 2014
	Convertible Notes	Convertible Notes
	Common stock
Convertible note financing	'	'
Aggregate amount of loan borrowed	'	$3
Interest rate (as a percent)	'	8.00%
Number of common shares into which convertible promissory notes and accrued interest converted	503,450	'
Share price (in dollars per share)	$6	'

Term_Loan_Amendment_Details

Term Loan Amendment (Details) (USD $)	Apr. 28, 2014	29-May-14	Apr. 30, 2014	Jan. 31, 2014	Sep. 30, 2014
	Convertible Notes	Term loan	Term loan	Term loan	Term loan
Term loan amendment	'	'	'	'	'
Extended interest only period through April 1, 2014	'	'	'	'3 months	'
Extended interest only period through July 1, 2014	'	'	'3 months	'	'
Face amount of notes	$3,000,000	'	'	'	'
Extended interest only period through January 1, 2015	'	'6 months	'	'	'
Total amount paid to Oxford finance	'	'	'	'	150,000
Amount offset against loan to be amortized to interest expense	'	'	'	'	$150,000

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)

0 Months Ended

9 Months Ended

0 Months Ended

29-May-14

Sep. 30, 2014

29-May-14

29-May-14

7-May-14

7-May-14

7-May-14

7-May-14

29-May-14

29-May-14

29-May-14

29-May-14

class

Minimum

Series C Preferred Stock

Series B Preferred Stock

Series A-1 Preferred Stock

Series A-2 Preferred Stock

Convertible subordinated promissory notes

Convertible subordinated promissory notes

Convertible preferred stock

Initial public offering

series

Automatic conversion, closing of an underwritten public offering

Automatic conversion, closing of an underwritten public offering

Automatic conversion, closing of an underwritten public offering

Automatic conversion, closing of an underwritten public offering

Common stock

Common stock

Common stock

Minimum

Minimum

Minimum

Minimum

Stockholders' equity

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued

'

'

'

'

'

'

'

'

'

'

'

9,166,667

Share price (in dollars per share)

'

'

'

'

'

'

'

'

'

$6

'

$6

Proceeds from initial public offering, net of underwriting discounts and commissions and other offering costs

'

'

'

'

'

'

'

'

'

'

'

$49,700,000

Number of common shares into which convertible promissory notes were converted

'

'

'

'

'

'

'

'

'

503,450

'

'

Number of common shares into which convertible preferred stock was converted

'

'

'

'

'

'

'

'

'

'

8,809,325

'

Aggregate principal amount converted

'

'

'

'

'

'

'

'

3,000,000

'

'

'

Gross proceeds from underwritten public offering

'

$49,743,641

'

'

$45,000,000

$45,000,000

$45,000,000

$45,000,000

'

'

'

'

Authorized shares of preferred stock

'

10,000,000

10,000,000

'

'

'

'

'

'

'

'

'

Authorized shares of common stock

'

150,000,000

150,000,000

'

'

'

'

'

'

'

'

'

Number of series of preferred stock that may be issued

'

'

'

1

'

'

'

'

'

'

'

'

Number of classes of Board

3

'

'

'

'

'

'

'

'

'

'

'

Term of Board member

'3 years

'

'

'

'

'

'

'

'

'

'

'

Number of classes elected at each annual meeting

1

'

'

'

'

'

'

'

'

'

'

'

Affirmative vote of all then-outstanding shares of capital stock for removal of directors (as a percent)

'

'

'

75.00%

'

'

'

'

'

'

'

'

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (Stock options, USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stock-Based Compensation Expense	'	'	'	'
Total stock-based compensation expense	$381,009	$259,294	$973,354	$1,095,452
Research and development	'	'	'	'
Stock-Based Compensation Expense	'	'	'	'
Total stock-based compensation expense	148,244	144,267	483,677	728,999
General and administrative	'	'	'	'
Stock-Based Compensation Expense	'	'	'	'
Total stock-based compensation expense	$232,765	$115,027	$489,677	$366,453

Income_Taxes_Details

Income Taxes (Details) (State, New Jersey, Sale of unused NOLs, USD $)	0 Months Ended
In Millions, unless otherwise specified	Feb. 27, 2014	Feb. 27, 2014
State | New Jersey | Sale of unused NOLs	'	'
Net operating losses	'	'
NOLs sold	'	$39.10
Net proceeds from sale	$3.60	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (SmartPharma, Commercial and business development consulting services, USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
SmartPharma | Commercial and business development consulting services	'	'
Related party transactions	'	'
Fees invoiced by the related party	$26,100	$100,400